# Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

> **NCT00092521** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5759 (actual)

## Conditions studied

- Cervical Cancer
- Genital Warts

## Interventions

- **BIOLOGICAL:** V501
- **BIOLOGICAL:** Comparator: Placebo
- **BIOLOGICAL:** Human Papillomavirus (HPV) 16 Monovalent

## Key facts

- **NCT ID:** NCT00092521
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2007-07
- **Final completion:** 2009-01
- **Target enrollment:** 5759 (ACTUAL)
- **Last updated:** 2015-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092521, "Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00092521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*